Fulgent Genetics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $323.9M+14.3% YoYTTM through 30 Jun 2026
Net Income -$84.4MTTM through 30 Jun 2026
Free Cash Flow -$103.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 39.1% |
| EBITDA Margin | -29.8% |
| Operating Margin | -35.9% |
| Net Margin | -26.1% |
Returns
-5.4%ROE
-5.0%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio6.34x
Net Debt-$335.6Mnet cash position
Cash & Equivalents$26.3M
Quality Metrics
Altman Z-Score4.79
Piotroski F-Score4 / 9
FCF Margin-32.0%
Rule of 40-23.7
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $322.7M
Diluted EPSFY2025: $-1.97
Dividend
No dividend
Capital Allocation
R&D Spend$56.8M
Capex Intensity6.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Laboratory Services | View detailsStrategic acquisitions of Bako Diagnostics and StrataDx are expected to help partially or fully offset the customer transition impact in the second half of 2026. | ||
| Therapeutic Development | View detailsTarget cash burn of approximately $26.0 million for therapeutic development in fiscal year 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.